Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How I treat cold agglutinin hemolytic anemia.

Clinical advances in hematology & oncology : H&O·2019
Same author

Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Brain and behavior·2019
Same author

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2019
Same author

Therapy of Transthyretin Cardiomyopathy.

Journal of the American College of Cardiology·2019
Same author

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Acta haematologica·2019
Same author

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

British journal of haematology·2019

Related Experiment Video

Updated: Apr 17, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

32.9K

Waldenström macroglobulinemia.

Pashtoon Murtaza Kasi1, Stephen M Ansell1, Morie A Gertz1

  • 1Mayo Clinic, Rochester, MN.

Clinical Advances in Hematology & Oncology : H&O
|February 14, 2015
PubMed
Summary

Waldenström macroglobulinemia (WM) is an incurable lymphoma. Advances in targeted therapies and novel agents are improving survival rates, though optimal treatment sequencing remains under investigation.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Waldenström macroglobulinemia (WM) is an indolent lymphoma involving bone marrow infiltration by lymphoplasmacytic cells and monoclonal immunoglobulin M.
  • Despite being considered incurable, WM patient survival has improved due to recent therapeutic advancements.

Purpose of the Study:

  • To review current therapeutic strategies for symptomatic Waldenström macroglobulinemia.
  • To discuss the role of MYD88 L265P and CXCR4 mutations in WM diagnosis, prognosis, and targeted therapy.
  • To present a treatment algorithm and compare key clinical trials for WM management.

Main Methods:

  • Literature review of therapeutic agents and clinical trials in WM.
  • Analysis of diagnostic and prognostic markers, including MYD88 and CXCR4 mutations.

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.7K

Related Experiment Videos

Last Updated: Apr 17, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

32.9K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.7K
  • Development of a risk-adapted treatment algorithm based on mSMART guidelines.

    • Main Results:

    • Established WM treatments include alkylating agents, nucleoside analogues, and monoclonal antibodies.
    • Novel agents like ibrutinib and rituximab show promise, but optimal sequencing is debated.
    • MYD88 L265P and CXCR4 mutations are crucial for targeted therapy development.

    Conclusions:

    • Recent therapeutic advances have improved WM survival, particularly for symptomatic patients.
    • Targeting specific mutations like MYD88 L265P offers new therapeutic avenues.
    • A structured approach, such as the mSMART algorithm, is essential for guiding treatment decisions in WM.